Product Description
Mechanisms of Action: NRI Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: GSK
Company Location: Europe
Company CEO: Emma Walmsley
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Depressive Disorder, Major
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT00057213 |
OHB20002 | P2 |
Completed |
Depressive Disorder, Major |
2007-04-01 |
2019-03-21 |
Treatments |
|
2005-002261-37 |
2005-002261-37 | P2 |
Terminated |
Depressive Disorder, Major |
2006-10-01 |
2022-03-12 |
Treatments |
|
NCT00057239 |
OHB20001 | P2 |
Completed |
Depressive Disorder, Major |
2004-05-01 |
2019-03-21 |
Treatments |
|
NCT00057226 |
OHB20003 | P2 |
Completed |
Depressive Disorder, Major |
2004-04-01 |
2019-03-21 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|